文章摘要
黄朝晖,华 东,李莉华,茆 勇,宋明旭.ERCC1 mRNA表达及基因多态性对胃癌辅助化疗预后的影响[J].南京医科大学学报,2008,28(4):453~456
ERCC1 mRNA表达及基因多态性对胃癌辅助化疗预后的影响
The prognostic impact of ERCC1 mRNA expression and polymorphism on gastric cancer patients treated with adjuvant chemotherapy
投稿时间:2007-07-17  
DOI:10.7655
中文关键词: 胃癌  化学治疗  ERCC1  基因多态
英文关键词: gastric cancer  chemotherapy  ERCC1  gene polymorphism
基金项目:无锡市科技局社会发展计划(CS055012,CLZ00612)
作者单位
黄朝晖 苏州大学附属第四医院肿瘤研究所江苏 无锡 214062 
华 东  
李莉华  
茆 勇  
宋明旭  
摘要点击次数: 1392
全文下载次数: 164
中文摘要:
      目的:探讨切除修复交叉互补基因(ERCC1) mRNA表达及118 C/T基因多态性与胃癌对奥沙利铂辅助化疗预后的关系。方法:根治术后胃癌患者62例,采用奥沙利铂为主的方案进行辅助化疗。采用半定量RT-PCR方法检测胃癌组织中ERCC1 mRNA水平。采用PCR-LDR(连接酶检测反应)检测ERCC1 118C/T基因多态。结果:62例胃癌组织ERCC1 mRNA表达水平的中位值为0.672;ERCC1 118 C/C、C/T和T/T基因型分别占51.6%(32/66)、43.5%(27/62)和4.8%(3/62)。ERCC1 mRNA高表达组(>0.672)无复发生存率和总生存率均显著低于低表达组(P < 0.05);携带C/T和T/T基因型患者与C/C基因型患者的无复发生存率和总生存率差异无显著性(P > 0.05)。多因素分析结果显示ERCC1 mRNA水平是影响患者预后的独立危险因素(P < 0.05),而ERCC1 118C/T多态与预后无关(P > 0.05)。结论:ERCC1 mRNA表达水平与接受奥沙利铂为主辅助化疗胃癌患者的预后有关,可用于其预后预测。
英文摘要:
      Objective:To investigate the association of ERCC1 mRNA levels and ERCC1 118 C/T polymorphism with the clinical outcome of gastric cancer patients treated with oxalipatinum-based adjuvant chemotherapy. Methods:Sixty-two gastric cancer patients received oxalipatinum-based adjuvant chemotherapy. The intratumoral ERCC1 mRNA expression was tested by semi-quantitative RT-PCR, and ERCC1 118 C/T polymorphism was tested by PCR-LDR(ligation detection reaction) method. Results:The median ERCC1 RNA level in 62 gastric cancer tissues was 0.672. The frequencies of ERCC1 118 C/C,C/T and T/T genotype were 51.6%(32/66),43.5%(27/62) and 4.8%(3/62),respectively. The recurrence-free and overall survival rate in patients with low level of ERCC1 mRNA(>0.672)were significantly higher than those in patients with high level(P < 0.05),while there was no significant difference found between patients with ERCC1 118 C/C and variant genotypes(T/T or C/T). Multivariate analysis showed that ERCC1 mRNA level was a potential predictor for relapse and survival in gastric cancer patients treated with platinum-based adjuvant chemotherapy(P < 0.05). ERCC1 118 C/T polymorphism was not associated with the disease prognosis. Conclusion:The ERCC1 mRNA level might be a useful predictive parameter for the relapse and survival of gastric cancer patients received with oxalipatinum-based adjuvant chemotherapy.
查看全文   查看/发表评论  下载PDF阅读器
关闭